Taken together, our work suggests that oral administration of cimifugin ameliorates DSS-induced colitis and its associated lung inflammation, which is associated with its inhibition of chemokine release, reduction of M1 macrophage infiltration and down-regulation of JAK1/STAT1 protein expression. The gene discussed is JAK1; the disease is colitis.